SCPX Stock Overview
Through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Scorpius Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.32 |
| 52 Week High | US$110.00 |
| 52 Week Low | US$0.28 |
| Beta | -0.35 |
| 1 Month Change | -52.12% |
| 3 Month Change | -57.30% |
| 1 Year Change | -99.57% |
| 3 Year Change | -99.95% |
| 5 Year Change | -99.95% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Dec 28
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Sep 02Heat Biologics names Anthony Manning as chief scientific advisor
May 10Heat Biologics EPS misses by $0.01, misses on revenue
May 05We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely
Apr 30Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years
Mar 07Shareholder Returns
| SCPX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.2% | -3.3% | -2.2% |
| 1Y | -99.6% | -1.9% | 23.9% |
Return vs Industry: SCPX underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: SCPX underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| SCPX volatility | |
|---|---|
| SCPX Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SCPX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SCPX's weekly volatility has decreased from 36% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 83 | Jeff Wolf | www.scorpiusbiologics.com |
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services.
Scorpius Holdings, Inc. Fundamentals Summary
| SCPX fundamental statistics | |
|---|---|
| Market cap | US$1.37m |
| Earnings (TTM) | -US$29.66m |
| Revenue (TTM) | US$10.04m |
0.1x
P/S Ratio0.0x
P/E RatioIs SCPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCPX income statement (TTM) | |
|---|---|
| Revenue | US$10.04m |
| Cost of Revenue | US$19.14m |
| Gross Profit | -US$9.09m |
| Other Expenses | US$20.57m |
| Earnings | -US$29.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.85 |
| Gross Margin | -90.52% |
| Net Profit Margin | -295.27% |
| Debt/Equity Ratio | 8.4% |
How did SCPX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 00:10 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Scorpius Holdings, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Justin Zelin | B. Riley Securities, Inc. |
| Kristen Kluska | Cantor Fitzgerald & Co. |